One such investigational approach involves BNT116, a personalized mRNA-based cancer vaccine, being evaluated in combination with the PD-1 inhibitor cemiplimab, in patients with advanced NSCLC exhibiting high PD-L1 expression. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.